摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-aminopyridin-2-yl)propan-1-one | 1412357-21-1

中文名称
——
中文别名
——
英文名称
1-(5-aminopyridin-2-yl)propan-1-one
英文别名
——
1-(5-aminopyridin-2-yl)propan-1-one化学式
CAS
1412357-21-1
化学式
C8H10N2O
mdl
——
分子量
150.18
InChiKey
GOGMISWNCSJIAQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    342.0±22.0 °C(Predicted)
  • 密度:
    1.129±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    56
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-(5-aminopyridin-2-yl)propan-1-one氢溴酸potassium carbonate溶剂黄146 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.5h, 生成
    参考文献:
    名称:
    [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS
    [FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
    摘要:
    本发明提供了一般式(I)的化合物,它们的盐和N-氧化物,以及它们的溶剂合物和前药(其中字符如描述中所定义)。一般式(I)的化合物是因子XIa的抑制剂,因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
    公开号:
    WO2013093484A1
  • 作为产物:
    描述:
    乙基溴化镁3-氨基-6-氰基吡啶盐酸 作用下, 以 乙醚 为溶剂, 反应 39.5h, 以16%的产率得到1-(5-aminopyridin-2-yl)propan-1-one
    参考文献:
    名称:
    发现四氢吲唑是一类新的有效的和体内有效的γ分泌酶调节剂。
    摘要:
    描述和优化的新型系列中央有效的γ分泌酶调节剂(GSM)提供了特权芳基咪唑基序的替代方案。手性双环四氢吲唑基胺取代的三唑并吡啶被鉴定为结构上不同的新型GSM系列。代表性化合物BI-1408(R-42)在口服剂量为30 mg / kg的大鼠中被证明具有中枢效力。
    DOI:
    10.1016/j.bmc.2018.04.053
点击查看最新优质反应信息

文献信息

  • [EN] TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE<br/>[FR] TRIAZOLO PYRIDINES UTILISÉES EN TANT QUE MODULATEURS DE GAMMA-SÉCRÉTASE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2019121596A1
    公开(公告)日:2019-06-27
    The present invention relates to triazolo pyridines of formula (II) and their use as modulators of -secretase. In particular, the present invention relates to compounds which interfere with -secretase and/or its substrate and therefore modulate the formation of Aβ peptides. Accordingly these compounds can be used for the treatment of Aβ-related pathologies, e.g. Alzheimer's disease.
    本发明涉及式(II)的三唑吡啶及其作为γ-分泌酶调节剂的用途。具体而言,本发明涉及干扰γ-分泌酶及/或其底物的化合物,从而调节Aβ肽的形成。因此,这些化合物可用于治疗与Aβ相关的病理,例如阿尔茨海默病。
  • Novel 2-pyridinecarboxamide derivatives
    申请人:Mitsuya Morihiro
    公开号:US20060258701A1
    公开(公告)日:2006-11-16
    The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
    本发明涉及一种化合物,具有激活葡萄糖激酶的效果,并可用作糖尿病治疗剂,其化学式表示为(I):[其中X1表示氮原子、原子、氧原子或类似物;R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物;D表示氧原子或原子;R和R3相同或不同,分别表示氢原子、低碳基或类似物;式(II)表示可选取代的5-至7-成员杂芳基团或类似物;式(III)表示单环或双环杂芳基团]或其药学上可接受的盐。
  • NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
    申请人:MITSUYA MORIHIRO
    公开号:US20100041660A1
    公开(公告)日:2010-02-18
    The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R 2 and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
    本发明涉及一种具有葡萄糖激酶激活作用并且可用作糖尿病治疗剂的化合物,其化学式为(I):[其中X1代表氮原子、原子、氧原子或类似物;R1代表6到10个成员的芳基基团、5到7个成员的杂芳基团或类似物;D代表氧原子或原子;R2和R3相同或不同,每个代表氢原子、低碳基团或类似物;化学式(II)代表可选取代的5到7个成员的杂芳基团或类似物;化学式(III)代表单环或双环杂芳基团]或其药学上可接受的盐。
  • Triazolo pyridines as modulators of gamma-secretase
    申请人:Boehringer Ingelheim International GmbH
    公开号:US11339161B2
    公开(公告)日:2022-05-24
    The present invention relates to triazolo pyridines of formula (II) and their use as modulators of #-secretase. In particular, the present invention relates to compounds which interfere with #-secretase and/or its substrate and therefore modulate the formation of Aβ peptides. Accordingly these compounds can be used for the treatment of Aβ-related pathologies, e.g. Alzheimer's disease.
    本发明涉及式(II)的三唑并吡啶及其作为#-分泌酶调节剂的用途。特别是,本发明涉及干扰#-分泌酶和/或其底物,从而调节Aβ肽形成的化合物。因此,这些化合物可用于治疗与 Aβ 有关的病症,如阿尔茨海默病。
  • Discovery and optimization of novel fatty acid transport protein 1 (FATP1) inhibitors
    作者:Tetsuyoshi Matsufuji、Mika Ikeda、Asuka Naito、Masakazu Hirouchi、Hideo Takakusa、Shoichi Kanda、Masanori Izumi、Jun Harada、Tsuyoshi Shinozuka
    DOI:10.1016/j.bmcl.2012.05.130
    日期:2012.8
    The discovery, optimization and structure-activity relationship of novel FATP1 inhibitors have been described. The detailed SAR studies of each moiety of the inhibitors combined with metabolite analysis led to the identification of the potent inhibitors 11p and 11q with improved blood stability. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多